Pembrolizumab plus ipilimumab for advanced melanoma : results of the keynote-029 expansion cohort
Georgina V. Long(The University of Sydney), John A. Thompson(Fred Hutch Cancer Center), Alexander Guminski(The University of Sydney), Alexander M. Menzies(The University of Sydney), Bernie Fitzharris(Christchurch Hospital), Jonathan Cebon(La Trobe University), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xinxin Shu(Georgetown University), Michael B. Atkins(Georgetown University), Catriona M. McNeil(Chris O’Brien Lifehouse), Andrew Hill(University of Auckland), Richard Kefford(Broad Institute), W. Hwu, Matteo S. Carlino(The University of Sydney), F. Stephen Hodi(Harvard University), Atkinson(Greenslopes Private Hospital), Michael B. Jameson(Waikato Hospital), A. Ribas, Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Unknown
August 1, 2016
Cited by 8
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k